Table 1. List of NSCLC patients with METex14 responded to MET tyrosine kinase inhibitors.

Number	Age/gender	Smoking status	Histology	MET exon 14 alterations	MET IHC	MET amplification	Best (duration of) response	Reference
1	80/F	NS	Adeno	Splice donor site mutation	3+	Yes	CR (>7 months) (PERIST) to cabozantinib	Paik et al., Cancer Dis 2015 (16)
2	78/M	ES	Adeno	Splice donor site deletion	3+	NR	PR to crizotinib (lung); PD to crizotinib (liver)	Paik et al., Cancer Dis 2015 (16)
3	65/M	ES	Adeno	Splice donor site mutation	NR	NR	PR (>7 months) to crizotinib	Paik et al., Cancer Dis 2015 (16)
4	90/F	NS	Adeno	Splice donor site mutation	NR	NR	PR (>5 months) to crizotinib	Paik et al., Cancer Dis 2015 (16)
5	86/M	NS	Adeno	Splice donor site deletion	2+	NR	PR (5 weeks) to crizotinib	Jenkins et al., Clin Lung Cancer 2015 (19)
6	71/M	ES	Adeno	Splice donor site mutation “D1028H”	NR	No	PR (>6 months) to crizotinib	Waqar et al., J Thorac Oncol 2015 (20)
7	76/F	ES	Adeno	Splice donor site mutation “D1010H”	NR	No	PR (>8 months) to crizotinib	Mendenhall et al., J Thorac Oncol 2015 (21)
8	82/F	ES	Large cell	Splice donor site mutation	3+	Yes*	PR (>5 months) to capmatinib	Frampton et al., Cancer Dis 2015 (17)
9	66/F	ES	SqCC	Splice donor site mutation	3+	NR	PR (>13 months) to capmatinib	Frampton et al., Cancer Dis 2015 (17)
10	74/F	ES	Sarcomatoid	Splice site mutation	NR	NR**	PR (>2 months) to crizotinib	Liu et al., J Clin Oncol 2015 (18)
11	61/M	NS	Sarcomatoid	Splice donor site mutation/H1094Y	NR	NR	PR (> 5 months) to crizotinib	Lee et al., J Thorac Oncol 2015 (22)

NSCLC, non-small cell lung cancer; METex14, MET exon 14 deletion; IHC, immunohistochemistry; M, male; F, Female; ES, ever-smoker; NS, never-smoker; Adeno, adenocarcinoma; SqCC, squamous cell carcinoma; NR, not reported; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. *, MET/CEP7 =2.3 (low amplification); **, polysomy (9 copies) of the MET exon 14 mutation allele.